PALVELLA THERAPEUTICS, INC. 8-K

What Happened
On February 24, 2026, Palvella Therapeutics, Inc. filed a Form 8‑K (Item 2.02) announcing a preliminary estimate of its liquidity: approximately $55.9 million in cash, cash equivalents and marketable securities as of December 31, 2025. The company said it has not completed its year‑end financial close procedures, so this figure is unaudited, preliminary and may differ materially from the amount that will appear in the consolidated financial statements for the year ended December 31, 2025.

Key Details

• Preliminary cash, cash equivalents and marketable securities: approximately $55.9 million (as of Dec 31, 2025).
• Filing date: February 24, 2026 (Form 8‑K, Item 2.02).
• Company management prepared the preliminary data; Ernst & Young LLP did not audit, review, compile or perform procedures and provides no assurance on this preliminary information.
• The amount is subject to change upon completion of the company’s financial statement closing procedures and does not present a complete view of financial condition.

Why It Matters
This disclosure gives investors an early snapshot of Palvella’s liquidity heading into 2026, which is important for assessing short‑term runway and funding needs. Because the figure is preliminary and unaudited, investors should treat it as an estimate and await the company’s finalized, audited year‑end financial statements (and related earnings/financial results disclosures) for a complete and verified view of Palvella’s financial condition.